HUTCHMED (China) Ltd
HCMNasdaq
$10.84
↓ -6.6%Jul 17 close · end-of-day
Price
1Y↓ -36.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$9.5B
Enterprise Value
$8.2B
P/E
20.8
P/S
17.3
P/B
7.6
EV/EBITDA
—
PEG
—
FCF Yield
-0.8%
Dividend Yield
—
Revenue (TTM)
$548.5M
Net Income (TTM)
$456.9M
Free Cash Flow (TTM)
-$78.8M
Gross Margin
—
Operating Margin
-7.1%
Net Margin
83.3%
ROE
36.9%
ROIC
—
Debt / Equity
0.1
Net Cash
$1.3B
Return 1Y
-38.1%
Company profile
HUTCHMED (China) Limited discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. It operates in Oncology/Immunology and Other Ventures segments. The company develops Savolitinib, an inhibitor for non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and gastric cancer (GC) In addition, it develops Tazemetostat, an inhibitors of EZH2 for the treatment of certain epithelioid sarcoma and follicular lymphoma patients.
- CEO
- Wei G. Su
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 1,760
- Website
- hutch-med.com
Earnings
No reported earnings periods on file.
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $228.0M | $356.1M | $426.4M | $838.0M | $630.2M | $548.5M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$196.7M | -$328.3M | -$407.7M | $18.4M | -$43.7M | -$39.2M |
| Net income | -$125.7M | -$194.6M | -$360.8M | $100.8M | $37.7M | $456.9M |
| Diluted EPS | -$0.18 | -$0.25 | -$0.43 | $0.12 | $0.04 | $0.52 |
| Operating cash flow | -$62.1M | -$204.2M | -$268.6M | $219.3M | $497,000.00 | -$64.7M |
| Free cash flow | -$70.0M | -$220.6M | -$305.3M | $186.6M | -$17.4M | -$78.8M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -86.3% | -92.2% | -95.6% | 2.2% | -6.9% | -7.1% |
| Net margin | -55.2% | -54.7% | -84.6% | 12.0% | 6.0% | 83.3% |
No quarterly data.
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.